368 related articles for article (PubMed ID: 22449230)
1. Primary cutaneous CD30 positive T-cell lymphoproliferative disorders with aberrant expression of PAX5: report of three cases.
Hagiwara M; Tomita A; Takata K; Shimoyama Y; Yoshino T; Tomita Y; Nakamura S
Pathol Int; 2012 Apr; 62(4):264-70. PubMed ID: 22449230
[TBL] [Abstract][Full Text] [Related]
2. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
Kempf W; Kutzner H; Cozzio A; Sander CA; Pfaltz MC; Müller B; Pfaltz M
Br J Dermatol; 2008 Jun; 158(6):1280-7. PubMed ID: 18410414
[TBL] [Abstract][Full Text] [Related]
3. Death receptor apoptosis signaling mediated by FADD in CD30-positive lymphoproliferative disorders involving the skin.
Clarke LE; Bayerl MG; Bruggeman RD; Mauger D; Ioffreda MD; Abou-Elella A; Helm KF
Am J Surg Pathol; 2005 Apr; 29(4):452-9. PubMed ID: 15767797
[TBL] [Abstract][Full Text] [Related]
4. SATB1 Defines a Subtype of Cutaneous CD30
Sun J; Yi S; Qiu L; Fu W; Wang A; Liu F; Wang L; Wang T; Chen H; Wang L; Kadin ME; Tu P; Wang Y
J Invest Dermatol; 2018 Aug; 138(8):1795-1804. PubMed ID: 29510190
[TBL] [Abstract][Full Text] [Related]
5. CD30-positive lymphoproliferative disorders arising after regional therapy for recurrent melanoma: a report of two cases and analysis of CD30 expression.
Gill K; Ariyan C; Wang X; Brady MS; Pulitzer M
J Surg Oncol; 2014 Sep; 110(3):258-64. PubMed ID: 24891295
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus in CD30 anaplastic large cell lymphoma involving the skin and lymphomatoid papulosis in South Korea.
Kim YC; Yang WI; Lee MG; Kim SN; Cho KH; Lee SJ; Lee MW; Koh JK
Int J Dermatol; 2006 Nov; 45(11):1312-6. PubMed ID: 17076712
[TBL] [Abstract][Full Text] [Related]
7. Fascin expression in CD30-positive cutaneous lymphoproliferative disorders.
Kempf W; Levi E; Kamarashev J; Kutzner H; Pfeifer W; Petrogiannis-Haliotis T; Burg G; Kadin ME
J Cutan Pathol; 2002 May; 29(5):295-300. PubMed ID: 12100631
[TBL] [Abstract][Full Text] [Related]
8. Loss of expression of 5-hydroxymethylcytosine in CD30-positive cutaneous lymphoproliferative disorders.
De Souza A; Tinguely M; Pfaltz M; Burghart DR; Kempf W
J Cutan Pathol; 2014 Dec; 41(12):901-6. PubMed ID: 25353265
[TBL] [Abstract][Full Text] [Related]
9. Expression of chemokines and chemokine receptors in cutaneous CD30+ lymphoproliferative disorders.
Yamaguchi T; Ohshima K; Karube K; Kawano R; Nakayama J; Suzumiya J; Kikuchi M
Br J Dermatol; 2006 May; 154(5):904-9. PubMed ID: 16634894
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous CD30-positive lymphoproliferative disorders with CD8 expression: a clinicopathologic study of 21 cases.
Plaza JA; Feldman AL; Magro C
J Cutan Pathol; 2013 Feb; 40(2):236-47. PubMed ID: 23189966
[TBL] [Abstract][Full Text] [Related]
11. Intralymphatic cutaneous anaplastic large cell lymphoma/lymphomatoid papulosis: expanding the spectrum of CD30-positive lymphoproliferative disorders.
Samols MA; Su A; Ra S; Cappel MA; Louissant A; Knudson RA; Ketterling RP; Said J; Binder S; Harris NL; Feldman AL; Kim J; Kim YH; Gratzinger D
Am J Surg Pathol; 2014 Sep; 38(9):1203-11. PubMed ID: 24805854
[TBL] [Abstract][Full Text] [Related]
12. CD30/Ki-1-positive lymphoproliferative disorders of the skin--clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group.
Paulli M; Berti E; Rosso R; Boveri E; Kindl S; Klersy C; Lazzarino M; Borroni G; Menestrina F; Santucci M
J Clin Oncol; 1995 Jun; 13(6):1343-54. PubMed ID: 7751878
[TBL] [Abstract][Full Text] [Related]
13. The differential diagnosis of CD8-positive ("type D") lymphomatoid papulosis.
McQuitty E; Curry JL; Tetzlaff MT; Prieto VG; Duvic M; Torres-Cabala C
J Cutan Pathol; 2014 Feb; 41(2):88-100. PubMed ID: 24118002
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of thymus and activation regulated chemokine and its receptor CCR4 in nodal and cutaneous anaplastic large-cell lymphomas and Hodgkin's disease.
Vermeer MH; Dukers DF; ten Berge RL; Bloemena E; Wu L; Vos W; de Vries E; Tensen CP; Meijer CJ; Willemze R
Mod Pathol; 2002 Aug; 15(8):838-44. PubMed ID: 12181269
[TBL] [Abstract][Full Text] [Related]
15. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin.
DeCoteau JF; Butmarc JR; Kinney MC; Kadin ME
Blood; 1996 Apr; 87(8):3437-41. PubMed ID: 8605362
[TBL] [Abstract][Full Text] [Related]
16. Primary cutaneous CD30+ lymphoproliferative disorder--a 10-year follow-up. A case report and differential diagnosis.
Szpor J; Dyduch G; Gałazka K; Bahyrycz J; Stój A; Tomaszewska R
Pol J Pathol; 2009; 60(1):43-8. PubMed ID: 19670703
[TBL] [Abstract][Full Text] [Related]
17. Potential involvement of Notch1 signalling in the pathogenesis of primary cutaneous CD30-positive lymphoproliferative disorders.
Kamstrup MR; Ralfkiaer E; Skovgaard GL; Gniadecki R
Br J Dermatol; 2008 Apr; 158(4):747-53. PubMed ID: 18241263
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of CD30-positive lymphoproliferative disorders for expression of CD95 and CD95L.
Sigel JE; Hsi ED
Mod Pathol; 2000 Apr; 13(4):446-51. PubMed ID: 10786813
[TBL] [Abstract][Full Text] [Related]
19. Contribution of longitudinal follow up and clinical pathological correlation in the diagnosis CD30-positive skin infiltrates.
De Souza A; Carter JB; Harris NL; Ferry JA; Duncan LM
J Cutan Pathol; 2015 Jul; 42(7):452-8. PubMed ID: 25931140
[TBL] [Abstract][Full Text] [Related]
20. Expression of CD44 and CD44v6 in primary cutaneous CD30 positive T-cell lymphoproliferative disorders.
Liang X; Smoller BR; Golitz LE
J Cutan Pathol; 2002 Sep; 29(8):459-64. PubMed ID: 12207739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
